Targeting Alpha-Synuclein: Breakthroughs in the Quest to Halt Parkinson's Progression

New alpha-synuclein structures could be targeted by Parkinson's therapies

PDF) Recent developments in the treatment of Parkinson's Disease

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers, Translational Neurodegeneration

Neuronal haemoglobin induces loss of dopaminergic neurons in mouse Substantia nigra, cognitive deficits and cleavage of endogenous α-synuclein

The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic

Parkinson's disease: Mechanisms, translational models and management strategies - ScienceDirect

α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies

IJMS, Free Full-Text

New hopes for disease modification in Parkinson's Disease - ScienceDirect

Nanotherapeutics approaches for targeting alpha synuclien protein in the management of Parkinson disease - ScienceDirect

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology, Molecular Neurodegeneration

The Odyssey of Alpha-synuclein and Neuroinflammatory Mediators as Potential Candidates in the Aetiology of Parkinson's Disease